Alembic Pharmaceuticals has informed about press release regarding the Company receives US Food & Drug Administration (USFDA) Approval Pramipexole Dihydrochloride Extended-Release Tablets, 0.375 mg, 0.75 mg, 1.5 mg, 2.25 mg, 3 mg, 3.75 mg, and 4.5 mg.
The above information is a part of company’s filings submitted to BSE.